Sovran Advisors’s AstraZeneca AZN Stock Holding History

Sovran Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$325K	Sell	1,885 -942	-33%	-$177K	0.02%	459
2026 Q1	$530K	Buy	2,827 +1,607	+132%	+$310K	0.04%	351
2025 Q4	$229K	Buy	+1,220	New	+$214K	0.02%	504
2025 Q3	–	Sell	-1,502	Closed	-$210K	–	521
2025 Q2	$210K	Buy	+1,502	New	+$211K	0.02%	470

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sovran Advisors's AZN Position: Q2 2026 in Review

Sovran Advisors reduced its AstraZeneca (AZN) stake by 33% in Q2 2026, selling an estimated $177K and leaving 1,885 shares worth $325K. The position accounts for 0.02% of the portfolio, ranked #459.

Sovran Advisors first reported a position in AZN in Q2 2025 and has held it in 4 quarters since. The position peaked at $530K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Sovran Advisors held 1,885 shares of AstraZeneca worth $325K as of Q2 2026.
Sovran Advisors sold 942 AstraZeneca shares in Q2 2026, an estimated $177K.
AstraZeneca made up 0.02% of Sovran Advisors's portfolio in Q2 2026, its #459 holding.
Sovran Advisors first reported a position in AstraZeneca in Q2 2025 and has held it in 4 quarters since.
Sovran Advisors's AstraZeneca position peaked at $530K in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Sovran Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.